Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1149-1158

  Heisen, M ^a   Treur, M J ^a   Van Der Hel, W S ^b   Frequin, S T F M ^c   Groot, M T ^b   Verheggen, B G ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b Novartis Pharma BV   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Cost analysis; Cost minimization; Disease modifying therapy; DMT; Fingolimod; Natalizumab; Relapsing; Remitting multiple sclerosis

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG COST; HEALTH CARE COST; HUMAN; MULTIPLE SCLEROSIS; NETHERLANDS; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; COST SAVINGS; COSTS AND COST ANALYSIS; HEALTH SERVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ECONOMETRIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NETHERLANDS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84869831029     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.707631     Document Type: Article

References (36)

1. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
2. Nationaal Kompas Volksgezondheid RIVM. Cijfers multiple sclerose (prevalentie, incidentie en sterfte naar leeftijd en geslacht). 2010. www.nationaalkompas. nl. Accessed June 22, 2012
3. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. HEPAC: health economics in prevention and care. Eur J Health Econ 2006;7(2 Suppl):S55-64
4. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77: 918-26
5. Weinshenker B. The natural history of multiple sclerosis. Neurol Clin 1995;13:119-46
6. Naci H, Fleurence R, Birt J, et al. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 2010;13:78-89
7. College voor Zorgverzekeringen. Farmacotherapeutisch Kompas. 2011. www.fk.cvz.nl. Accessed June 22, 2012
8. European Medicines Agency. Assessment report: Gilenya (EMEA/H/C/2202). European Medicines Agency, London, UK; 2011. p 1-117
9. Novartis Europharm Limited. Summary of product characteristics Gilenya. Novartis Europharm Limited, Horsham, UK; 2011. p 1-17
10. Elan Pharma International Ltd. Summary of product characteristics Tysabri. Elan Pharma International Ltd., Athlone, Ireland; 2006. p 1-36
11. Kappos L, Radue E, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 2010;362:387-401
12. Polman C, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med 2006; 354:899-910
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 2010;362:402-15
14. College voor Zorgverzekeringen. CFH rapport 12/02: fingolimod (Gilenya). College voor Zorgverzekeringen, Diemen, The Netherlands; 2012, p. 1-6
15. TLV Tandvå rds- och läkemedelsförmå nsverket (Swedish Dental and Pharmaceutical Benefits Agency). Swedish TLV report fingolimod (Gilenya) 11/08. TLV, Täby, Sweden; 2011. p 1-4
16. College voor Zorgverzekeringen. Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. 2010
17. Centraal Bureau voor de Statistiek. CBS Statline. 2011. http://statline.cbs.nl. Accessed June 22, 2012
18. Z-Index B.V. Z-Index, Taxe. 2011. http://www.z-index.nl/taxe. Accessed June 22, 2012
19. Hospital protocol 2. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1-4
20. Hospital protocol 3. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1-3
21. Hospital protocol 4. Hospital protocol: Fingolimod (Gilenya), Anonymous, The Netherlands; 2011. p 1-5
22. Hospital protocol 5. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2011. p 1-7
23. Hospital protocol 6. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2011. p 1-3
24. Nederlandse Zorgautoriteit. NZa Tariefapplicatie. 2011. http://dbc-tarieven. nza.nl/Nzatarieven. Accessed June 22, 2012
25. Hospital protocol 1. Hospital protocol: Natalizumab (Tysabri), Anonymous, The Netherlands; 2006. p 1-7
26. Association of British Neurologists. Revised (2009) Association of British Neurologists' guidelines for prescribing in multiple sclerosis, ABN, London, UK; 2009. p. 1-5
27. De Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-70
28. Donker G, van der Haar E. Waterpokken: vaccinatie invoeren of niet? Huisarts en Wetenschap 2009;52:165
29. Clifford DB, De Luca A, DeLuca A, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46
30. Del Santo F, Maratea D, Fadda V, et al. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012;68(4):441-8. Epub 2011 Nov 5
31. Goodman A. Multiple sclerosis: treatment update. 2008:1-10. http:// www.ucsfcme.com/2008/MNR08001/GoodmanMultipleSclerosisHighlights. pdf. Accessed June 22, 2012
32. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
33. Von Rosenstiel P, Hohlfeld R, Calabresi P, et al Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. In: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 16. Göteborg, Sweden; 2010, p 434
34. O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
35. European Medicines Agency. European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya. European Medicines Agency, London, UK; 2012. p 1-2
36. College voor Zorgverzekeringen. Medicijnkosten.nl. 2011. www.medicijnkosten. nl. Accessed June 22, 2012